Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

Seaside Therapeutics

Status: Completed

Conditions: Fragile X Syndrome

Treatments: Drug: STX209

Study type: Observational

Funder types: Industry

Identifiers

NCT00823368

22001A

Details and patient eligibility

About

The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001 will be offered participation in 22001A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or susceptibility to treatment with STX209. These same subjects will also be asked to contribute a blood sample for DNA (deoxyribonucleic acid) collection. The investigators will study the DNA to determine if STX209 works better in people with specific gene variations, or to find new gene variations that predict how well STX209 works.

Sex: All

Ages: 6 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001

Exclusion criteria

• Subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001

Trial design

0 participants in 2 patient groups

Arbaclofen followed by Placebo

Treatment:

Drug: STX209

Placebo followed by Arbaclofen

Treatment:

Drug: STX209